970*90
768
468
mobile

StemGenn Therapeutics Takes Up Franchise Route for Expansion

Nibedita Mohanta
Nibedita Mohanta Dec 26 2018 - 3 min read
StemGenn Therapeutics Takes Up Franchise Route for Expansion
"The current market size of anti-aging products itself has pegged Rs 40,000 crore and the market for anti-aging treatments would be even larger, " says Dr. Prabhu. Read on...

In conversation with Franchise India, Dr. Prabhu Mishra, CEO & Co-Founder, StemGenn Therapeutics, shares the expansion plans and what opportunities lie ahead of StemGenn Therapeutics.

Dr. Prabhu says, “StemGenn Therapeutics was started in 2014 with an innate desire to do something innovative in the arena of healthcare and medicine. Today, we not only have an effective cure for ailments but we are also working in areas like development of proprietary cell therapy products as well as revenue-generating physician and patient-based regenerative medicine/cell therapy training services, cell collection and cell storage facilities, and the operation of cell therapy clinics. The company has also opened the prestigious CosmoStem Institute of Regenerative Aesthetic Medicine in New Delhi where a lot of foreign doctors and medical experts come to receive training in stem cell and regenerative medicine.”

He adds, “The brand will see proliferation across the country very soon as we are embarking on the Franchise model for expansion.”

What encouraged you to take the franchise route?

We have proven scientific expertise in path-breaking treatment for some of the most severe and chronic medical treatments for which we have been providing training to doctors and scientists who belonged to different parts of India. We noticed that these doctors and scientists who took training from us, later on, relied on us for technical and scientific support for their patients in their own cities and states. This prompted us to reach out to needy patients across the country through the franchise model to provide Stem Cell Therapy and Regenerative Medicine. We have our scientific expertise and a world-class advisory committee that guided us to make this therapy affordable for mass level adoption which was a must before we embarked on expansion journey through Franchises.

What business opportunity lies ahead for StemGenn Therapeutics, What business potential lies ahead of the Franchisees?

The global Regenerative Medicine market is expected to touch USD 39 Billion by 2021, up from about USD 13 billion in 2016 and India will account for a huge share of that as there are a significant disease burden and limited healthcare opportunities. One of our focus areas is Total Body Rejuvenation that is anti-aging and longevity solutions and given the fact that the economy is doing well and there is growing affluence and income levels, the market for these solutions is mammoth. The current market size of anti-aging products itself has pegged Rs 40,000 crore and the market for anti-aging treatments would be even larger. We are also focusing on Stem Cells Therapy solutions for Infertility and Erectile Dysfunction which again presents a huge opportunity as there is a need for these solutions in every corner of the country.

A large slice of the revenue pie for the company would be on account of the franchise partners. Needless, to say they will do very well in their respective cities and regions.

What are your expansion plans?

We are planning to embrace the hub n spoke model. In 2019-20 we have a strategy to expand and have centers in Maharashtra, Madhya Pradesh, Andhra Pradesh and Karnataka. Our core focus of franchise is to train the doctors and scientists, along with conducting research, clinical trials and stem cell therapy in Regenerative Medicine, Aesthetic Medicine and Metabolic Medicine.

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online

Newsletter Signup

Share your email address to get latest update from the industry